{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:45:18Z","timestamp":1791089118351,"version":"4.1.0"},"reference-count":63,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Only anecdotal data are available on the pharmacokinetics (PK) of miltefosine in children suffering from visceral leishmaniasis (VL). While failure rates were higher in children with VL, steady-state concentrations appeared lower than those seen with adults. We hypothesized that the current linear dosage (in milligrams per kilogram of body weight) is too low for children and that a new dosing algorithm based on an appropriate body size model would result in an optimal exposure. A population PK analysis was performed on three historic pooled data sets, including Indian children, Indian adults, and European adults. Linear and allometric scaling of PK parameters by either body weight or fat-free mass (FFM) was evaluated for body size models. Based on the developed PK model, a dosing algorithm for miltefosine in children and adults was proposed and evaluated\n            <jats:italic>in silico<\/jats:italic>\n            . The population PK model employing allometric scaling fitted best to the pooled miltefosine data. Allometric scaling by FFM reduced between-subject variability, e.g., for drug clearance, from 49.6% to 32.1%. A new allometric miltefosine dosing algorithm was proposed. Exposure to miltefosine was lower in children than adults receiving 2.5 mg\/kg\/day: a\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            of 18.8 \u03bcg\/ml was reached by 90% of adults and 66.7% of children. The allometric daily dose resulted in similar levels of exposure to miltefosine for adults and children. The use of a new allometric dosing algorithm for miltefosine in VL patients results in optimal exposure to miltefosine in both adults and children and might improve clinical outcome in children.\n          <\/jats:p>","DOI":"10.1128\/aac.00292-12","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T05:40:21Z","timestamp":1337060421000},"page":"3864-3872","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":98,"title":["Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis"],"prefix":"10.1128","volume":"56","author":[{"given":"Thomas P. C.","family":"Dorlo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Pharmacy &amp; Pharmacology, Slotervaart Hospital, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology, Slotervaart Hospital, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology, Slotervaart Hospital, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.diagmicrobio.2008.09.014","article-title":"Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints","volume":"63","author":"Ambrose PG","year":"2009","unstructured":"AmbrosePG . 2009. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn. Microbiol. Infect. Dis. 63:38\u201342.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","article-title":"Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients","volume":"33","author":"Anderson BJ","year":"1997","unstructured":"AndersonBJ McKeeAD HolfordNH. 1997. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33:313\u2013327.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02725.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"key":"e_1_3_2_7_2","volume-title":"NONMEM users guides","author":"Beal SL","year":"2006","unstructured":"BealSL BoeckmannAJ SheinerLB. 2006. NONMEM users guides. Icon Development Solutions, Ellicott City, MD."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/380638"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/519690"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01484-10"},{"key":"e_1_3_2_11_2","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain E","year":"2011","unstructured":"ChatelainE IosetJ-R. 2011. Drug discovery and development for neglected diseases: the DNDi model. Drug Des. Devel. Ther. 5:175\u2013181.","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari A","year":"2011","unstructured":"Chrusciak-TalhariA . 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am. J. Trop. Med. Hyg. 84:255\u2013260.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/pbc.22051","article-title":"Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population","volume":"53","author":"Courter JD","year":"2009","unstructured":"CourterJD KutiJL GirottoJE NicolauDP. 2009. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr. Blood Cancer 53:379\u2013385.","journal-title":"Pediatr. Blood Cancer"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03630.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1128\/AAC.00866-09","article-title":"In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells","volume":"53","author":"da Luz RI","year":"2009","unstructured":"da LuzRI VermeerschM DujardinJC CosP MaesL. 2009. In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob. Agents Chemother. 53:5197\u20135203.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01761-09"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jchromb.2008.02.005","article-title":"Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry","volume":"865","author":"Dorlo TPC","year":"2008","unstructured":"DorloTPC . 2008. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 865:55\u201362.","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00014-08"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001436"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01559-10"},{"key":"e_1_3_2_21_2","unstructured":"German Drug Registration Authorities. 2008. Impavido 10\/50 mg Kapseln\u2014Fachinformation. German Federal Institute for Drugs and Medical Devices Bonn Germany."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/clpt.2009.262","article-title":"Dosing in children","volume":"87","author":"Holford N","year":"2010","unstructured":"HolfordN. 2010. Dosing in children. Clin. Pharmacol. Ther. 87:367\u2013370.","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1460-9592.2011.03782.x","article-title":"Prediction of morphine dose in humans","volume":"22","author":"Holford NHG","year":"2012","unstructured":"HolfordNHG MaSC AndersonBJ. 2012. Prediction of morphine dose in humans. Paediatr. Anaesth. 22:209\u2013222.","journal-title":"Paediatr. Anaesth."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4155\/fmc.11.102","article-title":"Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges","volume":"3","author":"Ioset J-R","year":"2011","unstructured":"IosetJ-R ChangS. 2011. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges. Future Med. Chem. 3:1361\u20131371.","journal-title":"Future Med. Chem."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00004"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912093412403"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_3_2_29_2","volume-title":"Abstr. Annu. Meet. Popul. Approach Group Eur","author":"Karlsson MO","year":"2008","unstructured":"KarlssonMO HolfordNHG. 2008. A tutorial on visual predictive checks, p 17, abstr 1434. Abstr. Annu. Meet. Popul. Approach Group Eur."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1155\/2008\/802710","article-title":"Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan","volume":"19","author":"Keynan Y","year":"2008","unstructured":"KeynanY . 2008. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can. J. Infect. Dis. Med. Microbiol. 19:394\u2013396.","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0378-4347(98)00469-1","article-title":"Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography","volume":"721","author":"Knebel NG","year":"1999","unstructured":"KnebelNG . 1999. Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 721:257\u2013269.","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm325"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00712-11"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/jps.22073","article-title":"Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics","volume":"99","author":"Mahmood I","year":"2010","unstructured":"MahmoodI. 2010. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J. Pharm. Sci. 99:2927\u20132933.","journal-title":"J. Pharm. Sci."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF00695989","article-title":"Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment","volume":"31","author":"Marschner N","year":"1992","unstructured":"MarschnerN K\u00f6ttingJ EiblH UngerC. 1992. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother. Pharmacol. 31:18\u201322.","journal-title":"Cancer Chemother. Pharmacol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000114"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11745-007-3026-8","article-title":"Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process","volume":"42","author":"M\u00e9nez C","year":"2007","unstructured":"M\u00e9nezC BuyseM FarinottiR BarrattG. 2007. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids 42:229\u2013240.","journal-title":"Lipids"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948040-00003"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.10-0661"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbamem.2004.01.010","article-title":"Hexadecylphosphocholine interaction with lipid monolayers","volume":"1661","author":"Rakotomanga M","year":"2004","unstructured":"RakotomangaM LoiseauPM Saint-Pierre-ChazaletM. 2004. Hexadecylphosphocholine interaction with lipid monolayers. Biochim. Biophys. Acta 1661:212\u2013218.","journal-title":"Biochim. Biophys. Acta"},{"key":"e_1_3_2_44_2","unstructured":"R Development Core Team. 2011. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria."},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jir816","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children","volume":"205","author":"Rubiano LC","year":"2012","unstructured":"RubianoLC . 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J. Infect. Dis. 205:684\u2013692.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000171"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp500"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-3156.2006.01647.x","article-title":"Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India","volume":"11","author":"Singh SP","year":"2006","unstructured":"SinghSP ReddyDCS RaiM SundarS. 2006. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop. Med. Int. Health 11:899\u2013905.","journal-title":"Trop. Med. Int. Health"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1086\/383321"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1086\/510588"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.78.210"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4269\/ajtmh.2009.81.387","article-title":"Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia","volume":"81","author":"Soto J","year":"2009","unstructured":"SotoJ . 2009. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am. J. Trop. Med. Hyg. 81:387\u2013389.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04367-0"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.inf.0000066877.72624.cb","article-title":"Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis","volume":"22","author":"Sundar S","year":"2003","unstructured":"SundarS . 2003. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. J. 22:434\u2013438.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021556"},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/BF02535537","article-title":"Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion","volume":"22","author":"van Blitterswijk WJ","year":"1987","unstructured":"van BlitterswijkWJ HilkmannH StormeGA. 1987. Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids 22:820\u2013823.","journal-title":"Lipids"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/648726","article-title":"Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan","volume":"50","author":"van Thiel PPAM","year":"2010","unstructured":"van ThielPPAM . 2010. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin. Infect. Dis. 50:80\u201383.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","article-title":"Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis","volume":"83","author":"V\u00e9lez I","year":"2010","unstructured":"V\u00e9lezI . 2010. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 83:351\u2013356.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5309.122"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.012579799"},{"key":"e_1_3_2_61_2","volume-title":"The global burden of disease: update","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. 2004. The global burden of disease: update. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/bmj.39281.645035.80","article-title":"Neglected tropical diseases","volume":"335","author":"Yamey G","year":"2007","unstructured":"YameyG HotezP. 2007. Neglected tropical diseases. BMJ 335:269\u2013270.","journal-title":"BMJ"},{"key":"e_1_3_2_63_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/bmj.325.7357.176","article-title":"The world's most neglected diseases","volume":"325","author":"Yamey G","year":"2002","unstructured":"YameyG TorreeleE. 2002. The world's most neglected diseases. BMJ 325:176\u2013177.","journal-title":"BMJ"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.clinthera.2011.09.010","article-title":"Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients","volume":"33","author":"Zobell JT","year":"2011","unstructured":"ZobellJT . 2011. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin. Ther. 33:1844\u20131850.","journal-title":"Clin. Ther."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00292-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00292-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:00:30Z","timestamp":1645452030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00292-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1128\/AAC.00292-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00292-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"2012-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}